CClinicalTrials.gg
Status unknownNCT02948166Updated May 5, 2017

Remote Endarterectomy and Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease

An interventional study of Angioplasty with stenting of the femoral artery and Open surgery in Steno-occlusive Desease of Femoro-popliteal Arterial Segment, sponsored by Meshalkin Research Institute of Pathology of Circulation. Status unknown at 1 site in Russian Federation. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Meshalkin Research Institute of Pathology of Circulation · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Comparison of two methods for revascularization of the superficial femoral artery: remote endarterectomy vs. stenting of the superficial femoral artery cin patients with steno-occlusive lesion of the femoro-popliteal segment of TASC C, D

Read the detailed description

Reported local percutaneous angioplasty and stenosis of femoral popliteal arteries indicate that the primary technical and clinical success above 95%. The technical success of recanalization of long occlusions femoral arteries less than 80%. Improvement of endovascular equipment designed for the treatment of total occlusions, increases the technical success of recanalization. The materials of the TASC II summarizes the results of several large studies that presented data on the operated segment artery patency at 56-73,7% within 2 years of observation. An alternative method of revascularization own femoral artery is remote endarterectomy. The two-year primary patency at remote endarterectomy is 86% (Moll F.L., Iio G.H. Closed superficial femoral artery endarterectomy: a 2-year follow up. Cardiovasc Surg. 1997; 5: 398-400). Primary assisted patency for 33 months 88% (Rosenthal D, Martin JD, Schubart PJ, Wellons ED. Remote. superficial femoral artery endarterectomy. J Cardiovasc Surg. (Torino) 2004; 45: 185-192). The length of the occlusion is not a limitation to the use of remote endarterectomy. Primary patency at 31 months was 60%.

02

Conditions studied

  • Steno-occlusive Desease of Femoro-popliteal Arterial Segment

Keywords

  • remote endarterectomy
  • Angioplasty with stenting of the superficial femoral artery
03

In context

Lead sponsor

Meshalkin Research Institute of Pathology of Circulation is the lead sponsor of 114 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with occlusive lesions of C and D type femoral artery and with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford)
  • Patients who consented to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Chronic heart failure of III-IV functional class by NYHA classification.
  • Decompensated chronic "pulmonary" heart
  • Severe hepatic or renal failure (bilirubin> 35 mmol / l, glomerular filtration rate \<60 mL / min);
  • Polyvalent drug allergy
  • Cancer in the terminal stage with a life expectancy less than 6 months;
  • Acute ischemic
  • Expressed aortic calcification tolerant to angioplasty
  • Patients with significant common femoral artery lesion
  • Patient refusal to participate or continue to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
174 participants (estimated)

Study arms

  • Active comparator
    Stenting of the femoral artery

    A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.

    Procedure: Angioplasty with stenting of the femoral artery

  • Experimental
    Open surgery

    Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.

    Procedure: Open surgery

Interventions

  • ProcedureAngioplasty with stenting of the femoral artery

    A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.

  • ProcedureOpen surgery

    Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

06

What researchers measure

Primary outcomes

  1. the change of lumen in target vessel

    Time frame: Baseline, 3 days after the operation, 6 month, 12 month, 2, 3 years

Secondary outcomes

  1. Number of participants with a successful procedure of revascularization.

    Time frame: During the operation.

  2. Number of participants with complications during the operation.

    Time frame: During the operation.

  3. Number of participants with limb salvage

    Time frame: Baseline, 3 days after the operation, 6 month, 12 month, 2, 3 years

07

Study locations

1 of 1 sites recruiting
  • Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology
    Novosibirsk, 630055, Russian Federation
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02948166
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible party
Sponsor
First posted
Oct 28, 2016
Start date
Jan 2016
Primary completion
Jan 2018 (estimated)
Completion
Jan 2019 (estimated)
Last update
May 5, 2017

Study contacts

Artem Rabtsun
Contact
a_rabtsun@meshalkin.ru
+79137078354
Andrey Karpenko
study director · cientific-Research Institute of Circulation Pathology named after Academician E. Meshalkin

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion